Many Physicians at Large Cancer Centers Help Manage Care for Individuals With Neuroendocrine Tumor
November 7th 2021Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers are able to manage care for individuals with many different physicians.
Expert Discusses Limitations of Vascular Calcification Treatments
November 7th 2021Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.
Implications of Early Vascular Aging in Patients With Chronic Kidney Disease
November 7th 2021Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what early vascular aging is, and what its implications are when it occurs in patients with chronic kidney disease.
Oncology Pharmacists Play a Huge Role in Caring for Individuals With Neuroendocrine Tumor
November 6th 2021Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses the importance of pharmacists in helping treat individuals with neuroendocrine tumors.
Nutrition Could Play a Big Role to Help Treatment of Neuroendocrine Tumors
November 6th 2021Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses the different treatment options that could help individuals with neuroendocrine tumors, emphasizing the importance of nutrition.
Expert Discusses Limitations and Risks of Integrative Medicine
November 6th 2021Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses what the different kinds or research shows about integrative medicine and the potential risk of this treatment.
Integrated Medicine Can Be Used in Conjunction With Oncology Treatment
November 6th 2021Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses what integrative medicine is and how it can be used in conjunction with established cancer treatments.
Pharmacists Play Important Role in Helping Individuals With Vascular Calcification
November 6th 2021Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the role pharmacists play in helping individuals with vascular calcification and chronic kidney disease.
Cancer Treatments Can Work Seamlessly With Integrative Oncology
November 6th 2021Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses how integrative medicine can be used with cancer treatments and what the benefits are.
Phosphate Binder Treatment Benefits Individuals With Advanced Stages of Chronic Kidney Disease
November 5th 2021Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses what the treatment options are to treat vascular calcification.
Overview of the Common Characteristics of Chronic Kidney Disease
November 5th 2021Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses his presentation at the American Society of Nephrology’s Kidney Week 2021 on vascular aging in chronic kidney disease.
Chronic Kidney Disease Elevates Risk of Vascular Calcification
November 5th 2021Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.
Nonsteroidal Mineralcorticoid Receptor Antagonists in Managing Hyperkalemia
November 5th 2021Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.